Type 2 diabetes prevention. Experts' Group position paper endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy
Magdalena Walicka(Central Clinical Hospital), Edward Franek(Mossakowski Medical Research Institute, Polish Academy of Sciences), Beata Wożakowska−Kapłon(Jan Kochanowski University), Tomasz Chomiuk(Medical University of Warsaw), Magdalena Olszanecka‐Glinianowicz(Medical University of Silesia), Mariusz Wyleżoł(Wojskowy Instytut Medycyny Lotniczej), Artur Mamcarz(Medical University of Warsaw), Krzysztof J. Filipiak(Postgraduate School of Molecular Medicine)
Cited by 3
Related Papers
Definition and diagnostic criteria of clinical obesity
|The Lancet Diabetes & Endocrinology|2025|1.3k
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Lactate dehydrogenase level as a COVID-19 severity marker
|The American Journal of Emergency Medicine|2020|109
Physical activity in metabolic syndrome
|Frontiers in Physiology|2024|89